Jan Marsal
1 – 10 of 46
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hyaluronic Acid-Conjugated Thermoresponsive Polymer-Based Bioformulation Enhanced Wound Healing and Gut Barrier Repair of a TNBS-Induced Colitis Injury Ex Vivo Model in a Dynamic Perfusion Device
(
- Contribution to journal › Article
-
Mark
Histologic Remission in Inflammatory Bowel Disease and Female Fertility : A Nationwide Study
2024) In Gastroenterology(
- Contribution to journal › Article
-
Mark
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
2024) In Digestive Diseases and Sciences(
- Contribution to journal › Article
- 2023
-
Mark
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients : comparison of retrospective cohorts
(
- Contribution to journal › Article
-
Mark
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
(
- Contribution to journal › Article
-
Mark
Long-term outcomes of vedolizumab in inflammatory bowel disease : the Swedish prospective multicentre SVEAH extension study
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
2022) In Alimentary Pharmacology and Therapeutics(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Letter: to switch or not to switch, that is the question—author's reply
(
- Contribution to journal › Letter